PharmaEngine to receive US$50 million in milestone payment as ONIVYDE's 2024 sales in Europe and Asia had reached second milestone

PharmaEngine and Haihe Biopharma enter into exclusive distribution agreement for LIPORAXEL®

PharmaEngine announces first patient dosed in Phase I trial of PEP07 for solid tumor cancers

ONIVYDE® obtains positive opinion from EMA's CHMP for new regimen in First-line Treatment of Metastatic PDAC

ONIVYDE® obtains TFDA Approval for the new regimen in First-line Treatment of Metastatic PDAC

ONIVYDE® obtains U.S. FDA approval of its supplemental new drug application

PharmaEngine announces TFDA approval of PEP07 Phase I clinical trial for solid tumor cancers

PharmaEngine announces first patient dosed in Phase I trial of PEP07 for hematological cancers

PharmaEngine announces EMA's acceptance of ONIVYDE®'s Type II Variation application

PharmaEngine files post-approval change application for a new indication of ONIVYDE® to TFDA